Ascendis Pharma A (ASND) Other Accumulated Expenses (2017 - 2026)

Ascendis Pharma A has reported Other Accumulated Expenses for 9 years, with the latest figure at $454.4 million in Q1 2026.

• Quarterly Other Accumulated Expenses rose 65.27% year-over-year to $454.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $454.4 million (up 65.27% YoY) and the FY2025 annual result came in at $446.7 million, up 39.82% from the prior year.
• Other Accumulated Expenses improved to $454.4 million in Q1 2026 per ASND's latest filing, from $446.7 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $454.4 million in Q1 2026 and troughed at $192.0 million in Q1 2024.
• A 4-year average of $319.2 million and a median of $297.9 million in 2024 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2025 and 2026: Other Accumulated Expenses jumped 35.38% in 2025, then surged 65.27% in 2026.
• Over 4 years, Other Accumulated Expenses stood at $200.3 million in 2023, then surged by 59.55% to $319.5 million in 2024, then jumped by 39.82% to $446.7 million in 2025, then climbed by 1.71% to $454.4 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $454.4 million, $446.7 million, and $381.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.